Loading...
XHKG
3759
Market cap6.19bUSD
Apr 03, Last price  
15.78HKD
1D
-3.66%
1Q
21.38%
IPO
-15.97%
Name

Pharmaron Beijing Co Ltd

Chart & Performance

D1W1MN
XHKG:3759 chart
No data to show
P/E
28.17
P/S
3.91
EPS
0.52
Div Yield, %
1.50%
Shrs. gr., 5y
14.91%
Rev. gr., 5y
31.74%
Revenues
11.54b
+12.39%
790,440,0471,128,037,5581,634,238,6802,294,118,0662,908,123,0333,757,160,0865,133,596,7587,443,769,72410,266,288,17911,537,996,314
Net income
1.60b
+16.48%
20,995,24073,846,442176,911,924230,857,087339,224,479547,191,4861,172,382,3871,661,028,5671,374,604,2241,601,096,033
CFO
2.75b
+28.50%
12,134,600216,939,062235,767,733552,215,324737,258,351938,586,3211,648,609,9572,058,043,8302,142,816,4162,753,538,934
Dividend
Jun 27, 20240.23614 HKD/sh
Earnings
Jun 06, 2025

Profile

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
URL
https://www.pharmaron.cn/
IPO date
Jan 28, 2019
Employees
19,733
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,537,996
12.39%
10,266,288
37.92%
Cost of revenue
8,866,701
7,749,700
Unusual Expense (Income)
NOPBT
2,671,295
2,516,588
NOPBT Margin
23.15%
24.51%
Operating Taxes
256,106
314,254
Tax Rate
9.59%
12.49%
NOPAT
2,415,189
2,202,334
Net income
1,601,096
16.48%
1,374,604
-17.24%
Dividends
(444,792)
(404,761)
Dividend yield
0.86%
0.75%
Proceeds from repurchase of equity
(830)
(1)
BB yield
0.00%
0.00%
Debt
Debt current
577,071
901,747
Long-term debt
9,370,060
5,975,290
Deferred revenue
152,375
Other long-term liabilities
799,328
112,093
Net debt
2,843,882
4,371,241
Cash flow
Cash from operating activities
2,753,539
2,142,816
CAPEX
(2,865,321)
Cash from investing activities
(2,250,833)
Cash from financing activities
3,915,262
FCF
697,679
(557,902)
Balance
Cash
6,720,255
2,242,846
Long term investments
382,994
262,950
Excess cash
6,526,350
1,992,482
Stockholders' equity
7,673,156
5,832,119
Invested Capital
16,872,959
15,040,089
ROIC
15.14%
16.63%
ROCE
11.42%
14.55%
EV
Common stock shares outstanding
1,775,248
1,184,187
Price
28.98
-36.07%
45.33
-15.22%
Market cap
51,446,683
-4.16%
53,679,195
-17.25%
EV
54,971,813
58,341,688
EBITDA
3,598,466
3,212,768
EV/EBITDA
15.28
18.16
Interest
182,192
167,312
Interest/NOPBT
6.82%
6.65%